Additionally, 223Ra treatment increased CD8+ and CD4+ T cell proliferation in murine bone-metastatic prostate cancer models, and combination with anti-PD-1 antibodies significantly prolonged survival [409]. The gene discussed is CD8A; the disease is prostate cancer.